# BVF INC/IL: Form 13F holdings

An institutional investment manager in San Francisco, CA. SEC CIK 1056807.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $3.91bn
- Positions: 44 (44 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1056807/000092189526002163/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [REVOLUTION MEDICINES INC (RVMD)](/companies/rvmd.md) | COM | $555.3m | 14.2% | 2,965,160 |  | Added +108,378 |
| [KYMERA THERAPEUTICS INC (KYMR)](/companies/kymr.md) | COM | $444.0m | 11.4% | 3,872,052 |  | Reduced −1,630,658 |
| XOMA ROYALTY CORPORATION | COM NEW | $322.7m | 8.3% | 7,593,303 |  | Added +5,003,000 |
| [MOONLAKE IMMUNOTHERAPEUTICS (MLTX)](/companies/mltx.md) | CLASS A ORD | $311.5m | 8.0% | 16,001,284 |  | Unchanged |
| GH RESEARCH PLC | ORDINARY SHARES | $232.5m | 5.9% | 8,650,158 |  | Unchanged |
| [STRUCTURE THERAPEUTICS INC (GPCR)](/companies/gpcr.md) | SPONSORED ADS | $180.7m | 4.6% | 3,366,823 |  | Reduced −92,535 |
| [NEKTAR THERAPEUTICS (NKTR)](/companies/nktr.md) | COM NEW | $166.9m | 4.3% | 2,391,075 |  | Reduced −168,520 |
| [MIRUM PHARMACEUTICALS INC (MIRM)](/companies/mirm.md) | COM | $123.6m | 3.2% | 1,056,027 |  | Reduced −528,700 |
| [XENCOR INC (XNCR)](/companies/xncr.md) | COM | $114.9m | 2.9% | 7,133,720 |  | Unchanged |
| ALKERMES PLC | SHS | $112.9m | 2.9% | 2,154,704 |  | Added +154,704 |
| [MONTE ROSA THERAPEUTICS INC (GLUE)](/companies/glue.md) | COM | $108.0m | 2.8% | 4,460,886 |  | Unchanged |
| [CULLINAN THERAPEUTICS INC (CGEM)](/companies/cgem.md) | COM | $104.7m | 2.7% | 5,750,683 |  | Unchanged |
| [PALVELLA THERAPEUTICS INC NE (PVLA)](/companies/pvla.md) | COM | $102.8m | 2.6% | 672,789 |  | Reduced −288,200 |
| [ZYMEWORKS INC (ZYME)](/companies/zyme.md) | COM | $95.4m | 2.4% | 3,649,142 |  | Reduced −85,000 |
| [KURA ONCOLOGY INC (KURA)](/companies/kura.md) | COM | $92.7m | 2.4% | 8,445,769 |  | Unchanged |
| [DISC MEDICINE INC (IRON)](/companies/iron.md) | COM | $84.4m | 2.2% | 1,153,612 |  | Reduced −118,700 |
| [STOKE THERAPEUTICS INC (STOK)](/companies/stok.md) | COM | $83.4m | 2.1% | 2,547,557 |  | Unchanged |
| [OLEMA PHARMACEUTICALS INC (OLMA)](/companies/olma.md) | COM | $66.3m | 1.7% | 5,295,893 |  | Unchanged |
| [ANNEXON INC (ANNX)](/companies/annx.md) | COM | $49.7m | 1.3% | 8,698,173 |  | Unchanged |
| CRESCENT BIOPHARMA INC. | COM | $49.5m | 1.3% | 2,748,763 |  | Unchanged |
| AC IMMUNE SA | SHS | $47.2m | 1.2% | 19,822,436 |  | Unchanged |
| [TYRA BIOSCIENCES INC (TYRA)](/companies/tyra.md) | COM | $47.1m | 1.2% | 1,476,196 |  | Reduced −500,000 |
| [SUTRO BIOPHARMA INC (STRO)](/companies/stro.md) | COM SHS | $41.6m | 1.1% | 1,251,788 |  | Unchanged |
| [IMMUNOCORE HLDGS PLC (IMCR)](/companies/imcr.md) | ADS | $41.1m | 1.1% | 1,294,463 |  | Unchanged |
| [AVALO THERAPEUTICS INC (AVTX)](/companies/avtx.md) | COM NEW | $38.4m | 1.0% | 2,075,545 |  | Added +442,700 |
| [4D MOLECULAR THERAPEUTICS IN (FDMT)](/companies/fdmt.md) | COM | $38.3m | 1.0% | 2,879,289 |  | Unchanged |
| [Q32 BIO INC (QTTB)](/companies/qttb.md) | COM | $29.9m | 0.8% | 2,350,000 |  | New +2,350,000 |
| [ANTERIS TECHNOLOGIES GLOBAL (AVR)](/companies/avr.md) | COM | $29.6m | 0.8% | 3,000,000 |  | Unchanged |
| [FOGHORN THERAPEUTICS INC (FHTX)](/companies/fhtx.md) | COM | $28.5m | 0.7% | 5,842,000 |  | Unchanged |
| [ABSCI CORPORATION (ABSI)](/companies/absi.md) | COM | $27.4m | 0.7% | 2,361,674 |  | New +2,361,674 |
| [ELEDON PHARMACEUTICALS INC (ELDN)](/companies/eldn.md) | COM | $24.8m | 0.6% | 6,293,282 |  | Unchanged |
| [INVIVYD INC (IVVD)](/companies/ivvd.md) | COM | $24.6m | 0.6% | 28,165,000 |  | Added +8,640,000 |
| [SAGIMET BIOSCIENCES INC (SGMT)](/companies/sgmt.md) | COM SER A | $19.3m | 0.5% | 2,500,000 |  | New +2,500,000 |
| [ONKURE THERAPEUTICS INC (OKUR)](/companies/okur.md) | COM CL A | $14.8m | 0.4% | 3,235,778 |  | Added +1,256,806 |
| [IMMUNIC INC (IMUX)](/companies/imux.md) | COM NEW | $11.8m | 0.3% | 765,295 |  | New +765,295 |
| [X4 PHARMACEUTICALS INC (XFOR)](/companies/xfor.md) | COM NEW | $10.4m | 0.3% | 2,233,742 |  | Unchanged |
| [IMAGENEBIO INC (IMA)](/companies/ima.md) | COM | $6.5m | 0.2% | 1,110,002 |  | Unchanged |
| [TSCAN THERAPEUTICS INC (TCRX)](/companies/tcrx.md) | COM | $5.5m | 0.1% | 5,564,290 |  | Unchanged |
| RESEARCH ALLIANCE CORP III | ORD SHS CL A | $5.3m | 0.1% | 500,000 |  | New +500,000 |
| [MOLECULAR PARTNERS AG (MOLN)](/companies/moln.md) | ADS | $5.1m | 0.1% | 1,353,968 |  | Unchanged |
| [TENAX THERAPEUTICS INC (TENX)](/companies/tenx.md) | COM NEW | $4.9m | 0.1% | 339,549 |  | Unchanged |
| ENTERA BIO LTD | SHS | $4.3m | 0.1% | 2,425,000 |  | New +2,425,000 |
| [INVENTIVA SA (IVA)](/companies/iva.md) | ADS | $2.6m | <0.1% | 686,040 |  | Unchanged |
| [ENGENE THERAPEUTICS (ENGN)](/companies/engn.md) | \*W EXP 10/31/202 | $274.1k | <0.1% | 945,402 |  | New +945,402 |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [COMPASS THERAPEUTICS INC (CMPX)](/companies/cmpx.md) | COM | $0 | 0.0% | 0 |  | Sold out −7,764,842 |
| ENGENE HOLDINGS INC | \*W EXP 10/31/202 | $0 | 0.0% | 0 |  | Sold out −945,402 |
| IMMUNIC INC | COM | $0 | 0.0% | 0 |  | Sold out −7,652,972 |
| [SEPTERNA INC (SEPN)](/companies/sepn.md) | COM | $0 | 0.0% | 0 |  | Sold out −1,353,249 |

Source: SEC EDGAR, Form 13F-HR, accession 0000921895-26-002163. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.